Breaking News

BioXcel and Takeda Partner

Will repurpose assets for orphan diseases

BioXcel Corporation, a provider of cloud-based Pharma big data solutions for discovering novel products, has entered into a partnership with Takeda Development Center Americas for the repurposing of assets across the gamut of rare diseases. Through this partnership, Takeda, a global research-based company with a focus on innovation in medicine, will gain access to and leverage BioXcel’s Big Data Innovation Lab, an integrated product discovery engine, and PharmGPS Orphan Disease Suite for drug discovery and repurposing.

Commenting on the partnership, BioXcel’s chief executive officer and chairman, Vimal Mehta, said, “We are pleased that Takeda will leverage our expertise in rare and ultra rare diseases to support their innovation and portfolio expansion initiatives. Discovering novel applications for existing molecules is an increasingly attractive strategy to address patient needs, while capitalizing on previous investments and de-risking clinical development. Our Big Data Innovation Lab facilitates the repurposing of the most attractive candidates applicable to a given disease.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters